**Summary Report on IQVIA's Earnings Conference Call**

**Highlights from the Quarter:**
- **Revenue Growth:** IQVIA reported first quarter revenue growth of 24% on a reported basis and 21% at constant currency, totaling $3,409 million, which exceeded expectations by $209 million. The growth was driven by strong operational performance and higher pass-throughs.
- **Adjusted EBITDA:** Increased by 32% year-over-year to $744 million, with margins expanding by 140 basis points despite higher pass-through revenue and lower-margin COVID work.
- **Adjusted Diluted EPS:** Grew by 45% to $2.18, reflecting the strong drop-through from adjusted EBITDA.
- **R&D Solutions:** Particularly strong with a 29.6% growth at actual FX rates. The backlog grew by 18.3% year-over-year to $23.2 billion.
- **Segment Performance:** Technology & Analytics Solutions revenue grew by 20.7% and R&D Solutions by 29.6%. However, CSMS revenue slightly declined by 1.5%.

**Operational Updates and Innovations:**
- **Commercial Technology:** Enhanced presence with a SaaS-based platform deployed in 14 countries optimizing sales force effectiveness using AI and machine learning.
- **eCOA Technology:** Continued strong demand for the Electronic Clinical Outcomes Assessment tool, now with over 125 studies and 300,000 patients enrolled.
- **Decentralized Trials:** Successful adaptation and expansion into new therapeutic areas, with significant patient recruitment using advanced solutions.

**Strategic Moves:**
- **Acquisition:** Completed the acquisition of the remaining interest in Q Squared Solutions, enhancing capabilities in laboratory services for clinical trials.

**Financial Position:**
- **Cash Flow and Debt Management:** Substantial free cash flow of $718 million, with net debt reduced to $9.9 billion and net leverage improved to 3.9 times trailing 12-month adjusted EBITDA.
- **Share Repurchase:** $50 million of shares repurchased, with $867 million authorization remaining.

**Forward Guidance:**
- **Revenue:** Raised full-year 2021 revenue forecast to $13,200 million to $13,500 million, reflecting operational momentum and an FX tailwind.
- **Adjusted EBITDA and EPS:** Increased guidance to $2,900 million to $2,965 million for adjusted EBITDA and adjusted diluted EPS guidance range to $8.50 to $8.75.

**Management and Organizational Changes:**
- New appointments in Investor Relations and Corporate Communications, along with leadership changes in the Treasury function.

**Conclusion and Outlook:**
IQVIA's first quarter showcased strong financial performance and strategic growth initiatives. With revised upward guidance for the full year, the company remains robustly positioned for sustained growth. Leadership changes are also set to invigorate the team with renewed focus and expertise.

**Next Steps:**
The financial community can look forward to details on Vision 2022 progress and further disclosures in upcoming investor conferences, enabling deeper insights into the company's strategic direction and financial health.